New vLife® 4.0 Focuses on Key Therapies and Platform AI Methodologies to Ease Restarting Operations After Shutdown
SOUTHBOROUGH, Mass. – (June 9, 2020) – Virtusa Corporation (NASDAQ GS: VRTU), a global provider of digital strategy, digital engineering, and IT services and solutions that help clients change and disrupt markets through innovation engineering, today announced a new marketplace that provides Healthcare and Life Sciences organizations with click, try, and buy access to applications and solutions that will increase efficiency and lower costs, including for virtual care.
Virtual care visits are predicted to exceed 1 billion in 2020 due to the COVID-19 pandemic, ongoing care management, mental health needs, and the 2020 flu season, according to a new ForresterNow report.
Except for frontline medical professionals and first responders, Healthcare and Life Sciences organizations have been restricted in the type of work that can be done because of COVID-19. Elective surgeries, wellness appointments, clinical trials of new medications and devices have all been on hold. In addition to restarting normal operations, Healthcare and Life Sciences organization must manage a massive backlog of patients, appointments, tests, and tracking results of clinical trials.
The new vLife marketplace incorporates more than 500 AI-based technologies from Virtusa and partners that will be in demand as organizations restart operations. vLife has been redesigned from the ground up to process these critical workloads quickly while avoiding skyrocketing costs.
New capabilities delivered in vLife include computer vision, synthetic data generation tools, platform AI, and faster AI algorithms to gain high-level understanding from data, digital images, and videos.
For example, using these new capabilities, patients recovering from surgeries can upload photos and videos that track the progress of recovering from orthopedic surgeries, new tools can decipher, analyze, predict, and prescribe the location of anatomical bodies in ultrasonic images in under 50 milliseconds, Generative Adversarial Networks (GAN) can create large sets of synthetic data from a handful of images, and automating biomedical image analysis to accelerate the understanding of human cells and disease.
“COVID-19 has disrupted the Global Healthcare ecosystem,” said Anthony Lange, SVP, healthcare and life sciences, Virtusa. "We prioritized our resources to launch vLife 4.0 to mitigate this disruption and enable our clients to engage with patients, members, and providers safely at scale while controlling costs."
Initial therapeutic areas vLife will address include Type 2 Diabetes, Oncology, Orthopedics, Renal, and infectious diseases, including COVID-19.
vLife service lines include:
Commercial Analytics. Converts data into insights to better understand and treat diseases, speed clinical trials, optimize medical and life sciences supply chains, and predict the future resources that will be needed.
Clinical Trials. A single resource to start, implement, and document clinical trials required before new medications, therapies, and medical devices are brought to market.
Patient Engagement. Keeps patients as informed as possible about options for treatment, medications, recuperation, and all other aspects of the healthcare system to improve wellness and self-manage elements of individual health.
Bioinformatics as a Service. Collect and analyze complex biological data, such as gene sequencing, without the massive investment in laboratory personnel or equipment.
Provider Services. To help patients seek treatment to prevent, alleviate, cure, or heal human illness, physical disability, or injury.
Payer Services. To help payers streamline processes and improve services.
Partner Offerings. To build and test how technologies from an extensive network of healthcare and life sciences organizations can work together to solve problems faster.
For additional information on vLife 4.0, please visit: virtusa.com/vlife